4. They are not the only company targeting CB2 generally. See slide 8 of that presentation linked above. While they are the only company targeting inflammation, there are several targeting pain, including big pharmas. Also, what should we make of their statement at the bottom of that slide that the others aren't targeting inflammation because their drugs penetrate the brain? Can we take that at face value? Why couldn't one of the big pharmas listed design a drug similar to CRBP's that doesn't penetrate the brain? Can we take their claim at face value? And why wouldn't penetrating the brain also be an issue in pain settings that all those other companies are otherwise pursuing?
5. While they are going into Phase 2 now, I don't see any links to the Phase 1 data on their Web site. So, I assume they have little or no actual evidence that their drug works in the clinic; I'm assuming all hope for now is simply based on pre-clinical data.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.